F. Galvagno

Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19

D. Sangiolo, A. Merlini, Federica Galvagno, 2022, Biomedicines.

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST

A. Pisacane, S. Ferrone, M. Aglietta, 2022, International journal of molecular sciences.

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade

G. Scagliotti, S. Novello, P. Bironzo, 2023, British Journal of Cancer.

Evaluation of Taxol cytotoxicity on B-CLL cells in vitro.

F. Morabito, F. Di Raimondo, F. Stagno, 1997, Leukemia & lymphoma.

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers

P. Circosta, L. Gammaitoni, M. Aglietta, 2022, British journal of haematology.